Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Microbiota-targeted strategies in IBD: therapeutic promise of 2'-fucosyllactose and beyond.
Journal: Therapeutic advances in gastroenterology
Published: April 13, 2025
Evaluation of a Novel Smart Capsule Bacterial Detection System Device for Diagnosis of Small Intestinal Bacterial Overgrowth.
Journal: Neurogastroenterology and motility
Published: July 23, 2024
Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System.
Journal: Inflammatory bowel diseases
Published: February 28, 2021
Development of a Novel Drug Delivery System to Deliver Drugs Directly to the Colonic Mucosa, Resulting in Improved Efficacy and Reduced Systemic Exposure for the Treatment of Ulcerative Colitis.
Journal: Crohn's & colitis 360
Published: February 28, 2021
Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis.
Journal: Alimentary pharmacology & therapeutics
Published: December 17, 2020
Challenges in IBD Research: Environmental Triggers.
Journal: Inflammatory bowel diseases
Published: March 29, 2019
Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Journal: Current medical research and opinion
Published: October 09, 2018
Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases.
Journal: Proteomes
Published: January 11, 2018
Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint.
Journal: Therapeutic advances in gastroenterology
Published: October 30, 2017
Food regulations: low FODMAP labeling and communication goals.
Journal: Journal of gastroenterology and hepatology
Published: December 21, 2016
Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Journal: Inflammatory bowel diseases
Published: April 09, 2016
Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.
Journal: Inflammatory bowel diseases
Published: January 09, 2015
Last Updated: 09/26/2026